Related Experiment Video
Updated: Jun 27, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR
D T Okuda1, R Srinivasan, J R Oksenberg
1UCSF Multiple Sclerosis Center, University of California, San Francisco, San Francisco, California 94117, USA.
Abstract:
Genetic susceptibility to multiple sclerosis (MS) is associated with the human leukocyte antigen (HLA) DRB1*1501 allele. Here we show a clear association between DRB1*1501 carrier status and four domains of disease severity in an investigation of genotype-phenotype associations in 505 robust, clinically well characterized MS patients evaluated cross-sectionally: (i) a reduction in the N-acetyl-aspartate (NAA) concentration within normal appearing white matter (NAWM) via (1)HMR spectroscopy (P = 0.025), (ii) an increase in the volume of white matter (WM) lesions utilizing conventional anatomical MRI techniques (1,127 mm(3); P = 0.031), (iii) a reduction in normalized brain parenchymal volume (nBPV) (P = 0.023), and (iv) impairments in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT-3) performance (Mean Z Score: DRB1*1501+: 0.110 versus DRB1*1501-: 0.048; P = 0.004). In addition, DRB1*1501+ patients had significantly more women (74% versus 63%; P = 0.009) and a younger mean age at disease onset (32.4 years versus 34.3 years; P = 0.025). Our findings suggest that DRB1*1501 increases disease severity in MS by facilitating the development of more T2-foci, thereby increasing the potential for irreversible axonal compromise and subsequent neuronal degeneration, as suggested by the reduction of NAA concentrations in NAWM, ultimately leading to a decline in brain volume. These structural aberrations may explain the significant differences in cognitive performance observed between DRB1*1501 groups. The overall goal of a deep phenotypic approach to MS is to develop an array of meaningful biomarkers to monitor the course of the disease, predict future disease behaviour, determine when treatment is necessary, and perhaps to more effectively recommend an available therapeutic intervention.
Insights
The human leukocyte antigen (HLA) DRB1*1501 allele is linked to increased multiple sclerosis (MS) severity. This genetic factor is associated with reduced brain volume, more white matter lesions, and cognitive decline in MS patients.
Area of Science:
- Neuroimmunology
- Genetics
- Clinical Neurology
Background:
- Multiple sclerosis (MS) susceptibility is strongly linked to the human leukocyte antigen (HLA) DRB1*1501 allele.
- Understanding genotype-phenotype associations is crucial for predicting MS disease course and severity.
Purpose of the Study:
- To investigate the association between HLA DRB1*1501 carrier status and multiple domains of MS disease severity.
- To explore the impact of DRB1*1501 on brain structure, function, and cognitive performance in MS patients.
Main Methods:
- Cross-sectional study of 505 clinically well-characterized MS patients.
- Utilized (1)HMR spectroscopy to measure N-acetyl-aspartate (NAA) concentration in normal-appearing white matter (NAWM).
- Employed conventional anatomical MRI to assess white matter (WM) lesion volume and normalized brain parenchymal volume (nBPV).
- Assessed cognitive function using the Paced Auditory Serial Addition Test (PASAT-3).
Main Results:
- DRB1*1501 carriers showed reduced NAA concentration in NAWM (P = 0.025).
- Increased WM lesion volume (P = 0.031) and reduced nBPV (P = 0.023) were observed in DRB1*1501+ patients.
- Impaired PASAT-3 performance (P = 0.004) and a higher proportion of women (P = 0.009) were associated with DRB1*1501.
- DRB1*1501+ patients had a younger mean age at disease onset (P = 0.025).
Conclusions:
- The HLA DRB1*1501 allele is associated with increased MS disease severity, impacting brain structure and cognitive function.
- DRB1*1501 may promote T2-lesion development, leading to axonal damage, neuronal degeneration, and brain volume loss.
- These findings highlight the potential of DRB1*1501 as a biomarker for monitoring MS progression and guiding therapeutic interventions.
Related Concept Videos
Multiple Sclerosis l: Introduction
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Multiple Allele Traits
Genetic Lingo
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...